Advertisement
Person › Details
Matthew Shinseki (Stern Investor Relations Inc. (Stern IR))
Shinseki, Matthew (Stern IR 201709)
Organisation | Stern Investor Relations Inc. (Stern IR) | |
Group | Precision Medicine Group (Group) | |
Product | public relations / investor relations / marcom (services) | |
Product 2 | LIFE SCIENCES | |
Pharnext S.A.. (9/5/17). "Press Release: Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference". Paris.
Pharnext SA (FR00111911287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the Rodman & Renshaw 19th Annual Global Investment Conference.
The presentation will take place as follows:
• Date: Tuesday, September 12th, 2017
• Time: 5:30 pm EDT (11:30 pm CEST)
• Venue: Lotte New York Palace Hotel in New York, New York
If you are interested in meeting the Pharnext management team during this event, please send an email to Matthew Shinseki at matthew@sternir.com.
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team. The company Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR00111911287). For more information, visit www.pharnext.com
CONTACTS:
Pharnext
Xavier Paoli
Chief Commercial Officer
contact@pharnext.com
+33 (0)1 41 09 22 30
Investor Relations (Europe)
MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1 212-362-1200
Financial Communication (France)
NewCAP
Emmanuel Huynh
pharnext@newcap.eu
+33 (0)1 44 71 20 40
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Margaux Pronost
pharnext@alizerp.com
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Russo Partners
Tony Russo
Scott Santiamo
tony.russo@russopartnersllc.com
scott.santiamo@russopartnersllc.com
+1 212-845-4251
+1 718-344-5843
Record changed: 2019-06-09 |
Advertisement
More documents for Matthew Shinseki
- [1] Pharnext S.A.. (10/19/17). "Press Release: First-Half 2017". Paris....
- [2] Pharnext S.A.. (9/5/17). "Press Release: Pharnext to Present at Rodman & Renshaw 19th Annual Global Investment Conference". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top